CNR1 and metabolic dysfunction-associated steatohepatitis: The present study demonstrated that the pharmacological blockade of CB1 improved hyperlipidemia (increased plasma TG and cholesterol levels), hyperinsulinemia (increased plasma insulin level), and increased inflammatory cytokine‐mediated NASH development in the obese db/db mice.